Fixed-dose combination of ceftolozane / tazobactam (Zerbaxa) for the treatment of hospital-acquired pneumonia


The fixed-dose combination of ceftolozane and tazobactam (trade name: Zerbaxa) has been approved in Germany since August 2019 for the treatment of hospital-acquired in adults. This fixed-dose combination is also an option for patients with that can be traced back to artificial ventilation in a hospital.

Pneumonia is an of the lungs' air sacs and the surrounding tissue.

Pneumonia that is contracted in a hospital, medical care center or outpatient practice is referred to as “nosocomial” . The lungs can sometimes become inflamed while a patient is being ventilated in a hospital for another condition.

Pneumonia is typically caused by bacteria. It can usually be treated effectively with . But when people catch in a hospital it can be particularly serious, and the treatment difficult. The most suitable antibiotic for treatment depends on the type of .

The fixed-dose combination of ceftolozane / tazobactam is an antibiotic: Ceftolozane kills the , and tazobactam enhances the effect by attacking an enzyme that would otherwise make ceftolozane inactive.


The fixed-dose combination of ceftolozane / tazobactam is given every 8 hours in the form of an infusion into the bloodstream (IV drip). The dose for hospital-acquired is 2 g ceftolozane and 1 g tazobactam. The treatment is stopped after 8 to 14 days, depending on the course of the .

The dose is lowered in patients with moderately to severely impaired kidney function or terminal kidney failure.

Depending on which germs are involved, other may be used as well.

Other treatments

Adults who have nosocomial can have individualized treatment with . Individualized antibiotic treatment takes into account the local presence of germs, (local) resistances to , the risk of by multiresistant , and the sensitivity of the to .


In 2020, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of ceftolozane / tazobactam when compared with the standard treatments for hospital-acquired in adults.

But the manufacturer didn’t provide any suitable data with which to do the assessment.

More information

This information summarizes the main results of a review produced by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The review was commissioned by the German Federal Joint Committee (G-BA) as part of the “early benefit assessment of medications.” On the basis of the review and the hearings received, the G-BA passed a resolution on the added benefit of the fixed-dose combination of ceftolozane / tazobactam (Zerbaxa).

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Ceftolozane/tazobactam (hospital-acquired pneumonia) – Benefit assessment according to §35a Social Code Book V. Dossier assessment; Commission A20-26. June 29, 2020. (IQWiG reports; Volume 937).

IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.

Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.

Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.

Comment on this page

What would you like to share with us?

We welcome any feedback and ideas. We will review, but not publish, your ratings and comments. Your information will of course be treated confidentially. Fields marked with an asterisk (*) are required fields.

Please note that we do not provide individual advice on matters of health. You can read about where to find help and support in Germany in our information “How can I find self-help groups and information centers?

Created on July 16, 2020
Next planned update: 2023


Institute for Quality and Efficiency in Health Care (IQWiG, Germany)

How we keep you informed

Follow us on Twitter or subscribe to our newsletter or newsfeed. You can find all of our films online on YouTube.